Loading...
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors lower serum urate levels and might have anti-inflammatory effects; however, clinical outcomes in patients with gout are unknown. In a retrospective study of Canadian patients (mean age, 66) with gout and type 2 diabetes, 4000 patients who initiated SGLT-2 inhibitors were compared with 4000 propensity-matched patients who initiated dipeptidyl peptidase-4 inhibitors (controls).
During mean follow-up of 19 months, patients who received SGLT-2 inhibitors had significantly fewer gout attacks (identified at primary care office visits) than did controls (5.6% vs. 8.3% annually); SGLT-2 patients also had significantly fewer attacks that required emergency department (ED) visits or hospitalizations (…